Choom Holdings Past Earnings Performance
Past criteria checks 0/6
Choom Holdings's earnings have been declining at an average annual rate of -38.1%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 78.6% per year.
Key information
-38.1%
Earnings growth rate
-17.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 78.6% |
| Return on equity | n/a |
| Net Margin | -84.1% |
| Last Earnings Update | 31 Dec 2021 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Choom Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 19 | -16 | 9 | 0 |
| 30 Sep 21 | 21 | -13 | 9 | 0 |
| 30 Jun 21 | 22 | -20 | 9 | 0 |
| 31 Mar 21 | 21 | -15 | 9 | 0 |
| 31 Dec 20 | 18 | -15 | 9 | 0 |
| 30 Sep 20 | 13 | -19 | 10 | 0 |
| 30 Jun 20 | 7 | -20 | 10 | 0 |
| 31 Mar 20 | 4 | -16 | 10 | 0 |
| 31 Dec 19 | 2 | -16 | 11 | 0 |
| 30 Sep 19 | 0 | -12 | 12 | 0 |
| 30 Jun 19 | 0 | -11 | 12 | 0 |
| 31 Mar 19 | 0 | -13 | 12 | 0 |
| 31 Dec 18 | 0 | -10 | 10 | 0 |
| 30 Sep 18 | 0 | -8 | 8 | 0 |
| 30 Jun 18 | 0 | -6 | 5 | 0 |
| 31 Mar 18 | 0 | -3 | 2 | 0 |
| 31 Dec 17 | 0 | -2 | 1 | 0 |
| 30 Sep 17 | 0 | -1 | 0 | 0 |
| 30 Jun 17 | 0 | -1 | 0 | 0 |
| 31 Mar 17 | 0 | 0 | 0 | 0 |
| 31 Dec 16 | 0 | -1 | 0 | 0 |
| 30 Sep 16 | 0 | -1 | 0 | 0 |
| 30 Jun 16 | 0 | -1 | 0 | 0 |
| 31 Mar 16 | 0 | -1 | 0 | 0 |
| 31 Dec 15 | 0 | -1 | 0 | 0 |
Quality Earnings: ORO is currently unprofitable.
Growing Profit Margin: ORO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ORO is unprofitable, and losses have increased over the past 5 years at a rate of 38.1% per year.
Accelerating Growth: Unable to compare ORO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: ORO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.